- BioCurity attended the Biotech Showcase January 10-12, 2022 and January 17-19, 2022 - BioCurity company presentation attached
BIOCURITY will attend the virtual BIOTECH SHOWCASE on January 10–12, 2022 and January 17–19, 2022
BIOCURITY will be present during the virtual Biotech Showcase on January 10-12, 2022, and January 17-19, 2022, to discuss partnering with other biopharmaceutical and life science leaders and investors.
BIOCURITY is a preclinical biotechnology company designed to prevent side effects of radiation which can enhance treatment outcomes, save healthcare dollars, and improve the quality of life for cancer patients. With 50% of cancer patients receiving radiation at some time in their treatment our drugs under development can transform radiation therapy for millions of cancer patients worldwide.
BIOCURITY
is a global leader in drug development using novel-based cerium oxide designed to prevent normal tissue damage from radiation therapy without interfering with the effectiveness of radiation on the cancerous tissue.
About the BIOTECH SHOWCASE:
The BIOTECH SHOWCASE is produced each year by Demy-Colton and EBD Group. The event being held virtual is in its 14th year and hosts small, and mid-cap private and public biotech and pharma companies, attracts investors representing over USD 400 Billion in capital, and highly motivated strategic partners in the life science ecosystem. This event will feature multiple tracks of curated presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings.
For more information on BIOCURITY
For more information on
BIOTECH SHOWCASE
- BioCurity press release January 12 2022
BioCurity Announces Presentation of Data on Cerium Oxide Nanoparticles to Sensitize Radiation for Head and Neck Cancer at ACRO 2022 Summit
January 12, 2022 09:00 AM Eastern Standard Time
JUPITER, Fla.--(BUSINESS WIRE)--BioCurity, a preclinical biotech company focused on developing novel mechanism-based nanoparticle drugs designed to transform radiation therapy for cancer patients worldwide, today announced an abstract regarding the Company’s proprietary technology on cerium oxide nanoparticle was accepted for a poster presentation at the American College of Radiation Oncology (ACRO) 2022 Summit, taking place March 9 - 12, 2022 at the Westin Fort Lauderdale Beach Resort in Fort Lauderdale, Florida.
The agenda for the ACRO 2022 Summit can be found here, with the poster presentations scheduled for March 11, 2022, from 12:00 – 1:00pm EST.
Details of the presentations are as follows:
Title: Harnessing Cerium Oxide Nanoparticles Combined with Tolfenamic Acid to Sensitize Head and Neck Cancer to Radiation
Session: Poster Walk with Professors - Bonnet
Presenter: Cheryl Baker, PhD, Scientific Co-Founder, BioCurity
About Cerium Oxide Nanoparticles
The production of hydrogen peroxide, a Reactive Oxygen Species (ROS) from radiation is a critical function for how radiation damages the DNA of cells of the tissue it passes through. BioCurity’s cerium oxide nanoparticles possess fast catalase activity in a normal tissue’s neutral pH environment and reduces radiation-induced hydrogen peroxide to molecular oxygen, thereby preventing radiation damage of normal tissue. BioCurity’s cerium oxide nanoparticles also possess superoxide dismutase activity in a cancerous tissue’s acidic pH environment and converts superoxide to hydrogen peroxide, thereby enhancing radiation-induced ROS damage of cancerous tissue.
BioCurity’s extensive preclinical studies in models of head and neck, lung, breast, pancreatic, prostate, and colorectal cancer show cerium oxide nanoparticles are regenerative and are not consumed in the reaction. Administration of cerium oxide nanoparticles at 1,000 times the effective dose did not produce toxicity in a small animal model.
About BioCurity
BioCurity Pharmaceuticals Inc. is a preclinical biotech company focused on developing novel mechanism-based nanoparticle drugs designed to transform radiation therapy for cancer patients worldwide. Approximately 50% of all cancer patients will receive radiation therapy at some point in their cancer treatment. With approximately 18 million new cancer patients a year globally, improving the outcome of radiation therapy is a world-unmet need. Fast track and orphan drug designations by the FDA for our drugs under development is possible. BioCurity is headquartered in Jupiter, Florida. For more information, please visit please visit BioCurity’s website and follow BioCurity on LinkedIn, Facebook, Instagram, and Twitter.
Contacts
MerchantCass Advisors, LLC - BioCurity Interim President and COO
Mr. Sam Merchant - BioCurity Co-Founder and Executive Chairman
Email: sam@biocurity.com
Phone: 1 (770) 814-4128
Ms. Nancy Cass - BioCurity Board Member
Email: nancy@biocurity.com
Phone: 1 (561) 889-5210
BioCurity Scientific Co-Founder
Dr. Cheryl Baker, PhD – BioCurity Scientific Co-Founder and Board Member
Email: cheryl.baker@biocurity.com
Phone: 1 (407) 432-6332
BioCurity Main Office
110 Front Street Suite 300
Jupiter Florida 33477
Phone Number: 1 (561) 708-6117
This news release contains forward-looking statements, including those relating to the product development of BioCurity Pharmaceuticals Inc. (the "Company" or "BioCurity"), clinical and regulatory timelines, market opportunity and other statements that are predictive in nature, or that depend upon or refer to future events or conditions. Forward-looking statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this news release. BioCurity's lead product candidate is in preclinical development and is not for sale or use. This news release is not an offer to buy any securities of the Company.
